The DarDar Trial remains the only trial in which
a new tuberculosis vaccine has shown efficacy in humans.
Not exact matches
The Gates Foundation brings treatment to the indigent and funds lifesaving research, including development of
new tuberculosis, malaria, and AIDS
vaccines.
«Taken together, these two studies suggest that the
new scalable
vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB
vaccine in humans since BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the
Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.
New vaccines against malaria,
tuberculosis and HIV are currently in field trials in the developing world.
The
TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of
new, safe and effective TB
vaccines that are accessible and affordable for all people.
BPRC applies molecular, biochemical and immunological know - how to provide
new vaccine and therapeutic strategies for malaria,
tuberculosis, HIV, hepatitis C and other infectious diseases.
Among other things, it features articles on
new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV
vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS,
Tuberculosis and Malaria.
TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of
new, safe and effective TB
vaccines that are accessible and affordable for all people.